Foghorn Therapeutics Inc.

NASDAQ:FHTX

Biotechnology

Healthcare
$1.79 +2.35%

+$0.10 today

Market cap
$107.33M
Beta
2.89
P/E (TTM)
-3.8
EPS (TTM)
-$1.08
52W Low $3.27High $6.95

Volume 0.53M

Average 0.15M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$86.10M

FY 2025 · Annual

Investing Cash Flow

$112.04M

FY 2025 · Annual

Financing Cash Flow

$1.02M

FY 2025 · Annual

-99.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(101.32M)(108.88M)(98.43M)(86.62M)(74.28M)
Depreciation & Amortization3.23M7.9M3.45M3.12M3.33M
Deferred Income Tax1.41M0000
Stock-Based Compensation8.38M016.19M11.89M10.4M
Change in Working Capital33.44M281.55M(41.88M)(32.27M)(32.14M)
Accounts Receivables(300M)300M000
Inventory(3.17M)0000
Accounts Payables135K1.61M846K(2.48M)481K
Other Working Capital336.48M(20.07M)(42.73M)(29.79M)(32.62M)
Other Non-Cash Items4.61M13.05M2.56M3.47M6.59M
Operating Cash Flow(50.25M)193.61M(118.11M)(100.41M)(86.1M)
Capital Expenditures(3.31M)(1.21M)(1.22M)(906K)(50K)
Acquisitions (Net)(39.49M)0000
Purchases of Investments(99.98M)(409.35M)(73.9M)(261.47M)(131.25M)
Sales of Investments139.47M166.23M219.58M232.47M243.34M
Other Investing Activities39.49M0000
Investing Cash Flow36.17M(244.32M)144.45M(29.9M)112.04M
Debt Repayment(21.21M)0000
Common Stock Issued42.21M1.76M0103.4M1.02M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.42M01.78M2.03M0
Financing Cash Flow22.42M1.76M1.78M105.43M1.02M
Effect of Forex Changes025K000
Net Change in Cash8.34M(48.92M)28.12M(24.88M)26.96M
Free Cash Flow(53.56M)192.4M(119.33M)(101.31M)(86.15M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$74.3M
+ D&A$3.3M
+ Stock-Based Comp$10.4M
+ Deferred Tax$0
- Working Capital-$32.1M
+ Other Non-Cash$6.6M
= Operating Cash Flow-$86.1M
- Capex-$50.0K
= Free Cash Flow-$86.1M

Analysis

FY2025 free cash flow is -$86.1M. FCF conversion is 116.0% of net income. Operating cash flow was -$86.1M, with capex of -$50.0K. The largest bridge item is Working Capital at -$32.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
3Initial statement of beneficial ownershipOct 5, 2026
SC 13G/ASC 13G/A filingOct 5, 2026
8-KCurrent reportOct 1, 2026

Does FHTX generate free cash flow?

Foghorn Therapeutics Inc. (FHTX) generated -$86.15M of free cash flow in fiscal 2025.

How much operating cash flow does FHTX produce?

Operating cash flow was -$86.10M, before capital expenditures of $50,000.00.